HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥KANDLELIT-001: Calderasib (MK-1084), Alone or in Combination, for KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer (mNSCLC) 🎙️ @nahit_sendur 🔢2680RO 🎯With Pembrolizumab (PD-L1 TPS≥1%): ORR 72%, Median PFS 28.9mo (n=98); TPS≥50% ORR 87%; 🎯Monotherapy ORR 27%; Calderasib+Pembro+Chemo ORR 65%, PFS 15.1mo ☑️NCT05067283 🔗 https://t.co/p4tFUd6NwV @OncoAlert @Larvol @myESMO @IASLC @KRASKickers
热度 12 · 8 赞 · 0 回复 · 4 转发
会议摘要
NCT05067283NCT05067283按 - **标题 / Title：** A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) 对上
- **标题 / Title：** A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)读摘要原文 →来源：HHorinouchi · x.com